Oragenics (OGEN) Revenue (2010 - 2023)
Oragenics' (OGEN) quarterly Revenue came in at $7466.0 in Q3 2023, down 91.32% YoY from $86047.0 in Q3 2022, and down 43.28% on a QoQ basis from $13163.0 in Q2 2023.
Oragenics (OGEN) Revenue (2010 - 2023) Analysis & Trends
Oragenics (OGEN) has 7 years of Revenue data on file, last reported at $7466.0 in Q3 2023.
- Quarterly Revenue fell 91.32% year-over-year to $7466.0 in Q3 2023, while the trailing twelve-month figure through Dec 2023 was $37653.0 (down 71.37% YoY) and the FY2023 annual result came in at $37653.0, down 71.37% from the prior year.
- Revenue declined to $7466.0 in Q3 2023, from $13163.0 in the prior quarter.
- In the past five years, Revenue ranged from a high of $86047.0 in Q3 2022 to a low of $7466.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | Oragenics | 2.38 Mn | 2.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 7,466.00 |
| Jun 30, 2023 | 13,163.00 |
| Mar 31, 2023 | 17,024.00 |
| Sep 30, 2022 | 86,047.00 |
| Jun 30, 2022 | 30,391.00 |
| Mar 31, 2022 | 15,083.00 |
| Dec 31, 2014 | 220,504.00 |
| Sep 30, 2014 | 201,010.00 |
| Jun 30, 2014 | 303,752.00 |
| Mar 31, 2014 | 214,660.00 |
| Dec 31, 2013 | 434,784.00 |
| Sep 30, 2013 | 253,374.00 |
| Jun 30, 2013 | 167,668.00 |
| Mar 31, 2013 | 176,407.00 |
| Dec 31, 2012 | 430,582.00 |
| Sep 30, 2012 | 264,248.00 |
| Jun 30, 2012 | 256,407.00 |
| Mar 31, 2012 | 380,527.00 |
| Dec 31, 2011 | 396,590.00 |
| Sep 30, 2011 | 350,351.00 |